Defining high-quality NSCLC care at U.S. cancer centers.

Authors

null

Mark A. Socinski

AdventHealth Cancer Institute, Orlando, FL

Mark A. Socinski, Leigh Boehmer

Organizations

AdventHealth Cancer Institute, Orlando, FL, Association of Community Cancer Centers, Rockville, MD

Research Funding

Pharmaceutical/Biotech Company
AstraZeneca

Background: While clinical guidelines for non-small cell lung cancer (NSCLC) provide recommendations on individual components of care and advocate multidisciplinary collaboration, guidance spanning the complete patient journey is lacking. We aimed to compile quality-focused recommendations for the multidisciplinary team and selected clinical criteria for ideal NSCLC care, and propose a new set of metrics encompassing the entire care continuum. These metrics would be used as a new benchmark for ideal NSCLC care via the Association of Community Cancer Centers’ (ACCC) national quality care initiative for patients with advanced (stage III/IV) NSCLC. Methods: The ACCC convened an expert steering committee of multidisciplinary specialists and representation from patient advocacy to compile evidence-based recommendations via a systematic search of clinical and quality care guidelines and peer-reviewed journals. Quality recommendations were organized within key care areas of the patient journey: care coordination and patient education, diagnosis and biomarker testing, staging and treatment planning, and survivorship. Results: A total of 32 recommendations were included across the 4 key NSCLC care areas. Key quality recommendations are listed (Table). Conclusions: The full set of recommendations define ideal NSCLC care and serve as a valuable guide for multidisciplinary practice and quality improvement initiatives.

Key quality recommendations for ideal stage III/IV NSCLC care.

Care coordination and patient educationDiagnosis and biomarker testingStaging and treatment planningSurvivorship
· Standardize patient participation in shared decision-making
· Educate patients on all aspects of NSCLC management, including diagnosis, staging, and treatment
· Provision of access to an MDT care navigator for information on financial aspects of treatment
· Multidisciplinary evaluation of suspicious findings
· MDT coordination for efficient biopsy collection
· Use of broad molecular profiling to identify actionable and rare mutations
· Incorporation of invasive staging procedures for increased sensitivity and specificity
· Staging and use of appropriate techniques is paramount to define treatment planning
· Biomarker tests to inform all treatment-related decisions
· Repeat biopsy and/or plasma testing in the setting of insufficient tissue
· Implementation of standard protocols for short- and long-term surveillance
· Provision of survivorship care plans to all patients diagnosed with advanced NSCLC

MDT, multidisciplinary team; NSCLC, non-small cell lung cancer

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2020 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

On-Demand Poster Session: Quality, Safety, and Implementation Science

Track

Quality, Safety, and Implementation Science

Sub Track

Quality Improvement Research and Implementation Science

Citation

J Clin Oncol 38, 2020 (suppl 29; abstr 229)

DOI

10.1200/JCO.2020.38.29_suppl.229

Abstract #

229

Poster Bd #

Online Only

Abstract Disclosures

Similar Abstracts

First Author: Mark A. Socinski

First Author: Matthew Smeltzer

First Author: Laura LaNiel Tenner

Abstract

2023 ASCO Quality Care Symposium

Using clinical pathways to identify patient candidates for survivorship in testicular cancer.

First Author: Matthew Rice